Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
11/2005
11/30/2005EP1599482A1 Pyrazolo 1,5-a pyrimidine derivatives
11/30/2005EP1458381B1 Triazoles as oxytocin antagonists
11/30/2005EP1146877B1 (2-imidazolin-2-ylamino) quinoxalines for the treatment of neural injury
11/30/2005EP0963200B9 Compositions for inhibition of angiogenesis comprising thalodomide and a nsaid
11/30/2005CN1703248A Drug for auditory dysfunction
11/30/2005CN1229381C Macrolides compound
11/30/2005CN1229373C Piperidinee derivatives as neurokinin1 antagonists
11/30/2005CN1229371C Benzopyranyl guanidine derivtives, process for preparation thereof and pharmaceutical compositions containing them
11/30/2005CN1229362C Bicyclic guanidine derivatives and therapeutic uses thereof
11/30/2005CN1229351C Heterocyclic compounds and methods to treat cardiac failure and other disorders
11/30/2005CN1229349C Pyridine-3-carboxylic acid derivative
11/30/2005CN1229343C Chemotactic factor receptor active regulator
11/30/2005CN1229335C Nervinolin derivatives
11/30/2005CN1229138C Method for accelerating rate of mucociliary clearance
11/30/2005CN1229137C New therapeutic uses of SMR1 peptides
11/30/2005CN1229136C Laerimal gland specific emulsions for topical application to ocular tissue
11/30/2005CN1229114C Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
11/30/2005CN1229110C Ophthalmic compositions containing galactomannan polymers and borate
11/29/2005US6969770 reacting an alpha-keto carboxy acid ester or derivative with a pyrrolidinone to form an intermediate, subjecting the intermediate to asymmetric hydrogenation using a chiral catalyst to form the end product
11/29/2005US6969729 An indole or benz(g)indole-2,3-dione-3-oxime compounds; therapeutic treatment of respiratory disorders, urogenital disorders, cardiovascular disorders, brain and psychological disorders, gastrointestinal disorders
11/29/2005US6969723 preferably antagonists used in the therapeutic and/or preventive treatment of disfunctions of the heart, kidney, respiratory system, central nervous system
11/29/2005US6969719 Such as 3-((3-bromo-4-hydroxyphenyl)methyl)-5-ethyl-7,8-dihydro-2-(tetrahydro-2H -pyran-4-yl)amino)-3H-imidazo(2,1-b) purin-4(5H)-one for treating sexual disorders
11/29/2005US6969717 Azaindole kinase inhibitors
11/29/2005US6969714 Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
11/29/2005US6969524 Interferon complex and medicinal use thereof
11/29/2005US6969383 Method for treating severe tinnitus
11/29/2005CA2288445C 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
11/24/2005WO2005110444A1 Therapeutic or preventive agent for eye disease
11/24/2005WO2005110438A2 Methods and products related to the intracellular delivery of polysaccharides
11/24/2005WO2004091630A8 Remedies for diseases to be applied to eye
11/24/2005US20050261496 3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1H-indole-2-carboxamide; inhibiting, modulating and/or regulating signal transduction of both receptor and non-receptor tyrosine kinases; anticarcinogenic, -diabetic, -arhtritic, -inflammatory agents; psoriasis; angiogenesisinhibitors; liver cirrhosis
11/24/2005US20050261343 Anthranilamides and their use as pharmaceutical agents
11/24/2005US20050261317 Inhibitors of human phosphatidylinositol 3-kinase delta
11/24/2005US20050261313 For angiogenesis mediated diseases; cancer; acylation, cyclization and Heck-type reduction
11/24/2005US20050261305 Cyclic protein tyrosine kinase inhibitors
11/24/2005US20050261293 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/24/2005US20050261281 Pharmaceutical compounds
11/24/2005US20050261269 New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them
11/24/2005US20050261267 Pharmaceutical formulation
11/24/2005US20050261248 New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives
11/24/2005US20050260601 Recombinant mutants of rhabdovirus and methods of use thereof
11/24/2005US20050260280 Contact lens and eye drop rewetter compositions and methods
11/24/2005US20050260230 Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins
11/24/2005US20050260174 Systems and methods for treating patients with processed lipoaspirate cells
11/24/2005CA2565249A1 Intravitreal implants in conjunction with photodynamic therapy to improve vision
11/24/2005CA2565067A1 Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision
11/24/2005CA2564948A1 An estradiol derivative or an estratopone derivative containing sustained release intraocular implant as well as related methods of manufacturing
11/24/2005CA2507712A1 Pharmaceutical compounds
11/24/2005CA2507710A1 Tricyclic pyrazole derivatives and their use as cb1 or cb2 modulators
11/23/2005EP1598371A1 Medicinal composition for ophthal use containing acetylated hyaluronic acid
11/23/2005EP1598349A1 Novel 2-pyridinecarboxamide derivatives
11/23/2005EP1598340A1 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598339A1 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598338A1 1-(4-piperidinyl)-1,3-dihydro-2h-indole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
11/23/2005EP1598335A1 Prostaglandin derivatives
11/23/2005EP1598077A1 Use of the neurotoxic component of botulinum toxins for the treatment of a spastic muscle
11/23/2005EP1598071A1 Superoxide anion decomposing agent
11/23/2005EP1596850A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function
11/23/2005EP1200831B1 Modulating binding site on potassium channels used for screening
11/23/2005EP1112106B1 Serotonergic 5ht2 agonists for treating glaucoma
11/23/2005EP1021402B1 Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
11/23/2005CN1701068A Novel compounds and their use
11/23/2005CN1701061A New compounds for the inhibition of rotamases and use thereof
11/23/2005CN1700922A 3, 10, and 12a substituted tetracycline compounds
11/23/2005CN1700913A Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
11/23/2005CN1700894A Methods of treating dry eye disease with lantibiotics
11/23/2005CN1698602A Usage of pyrazoline derivant in the drug preparation for preventing and/or treating cell breeding disease
11/23/2005CN1228337C Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
11/23/2005CN1228053C Eye drop containing diuridine phosphoric acid
11/23/2005CN1228047C Remedies for heratoconjunctival diseases containing farnesyl acetate as the active ingredient
11/22/2005US6967210 Multiple sclerosis, brain disorders, analgesics
11/17/2005WO2005108400A1 Pyridoquinazoline derivatives having heterobicyclic substituents
11/17/2005WO2005108399A1 Imidazopyridine compound
11/17/2005WO2005108396A1 Therapeutic agent for keratoconjunctiva disorder
11/17/2005WO2005108370A1 Benzene compounds
11/17/2005WO2004108945A3 Oligonucleotide modulation of cell adhesion
11/17/2005WO2004078140A3 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
11/17/2005US20050256333 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis
11/17/2005US20050256315 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
11/17/2005US20050256311 Pyrimidine compounds
11/17/2005US20050256299 Vaccines
11/17/2005US20050256201 Phenethanolamine derivatives
11/17/2005US20050256160 Beta-alanine derivatives and the use thereof
11/17/2005US20050256140 Condensed pyridines and pyrimidines with tie2 (tek) activity
11/17/2005US20050256122 Substituted pyridazinones
11/17/2005US20050256117 Ophthalmic compositions for treating ocular hypertension
11/17/2005US20050256081 Tetracycline derivatives for the treatment of ocular pathologies
11/17/2005US20050256079 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
11/17/2005US20050255549 IRAK-4: compositions and methods of use
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
11/17/2005CA2774146A1 Steroid intraocular implants having an extended sustained release for a period of greater than 2 months
11/17/2005CA2566398A1 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
11/17/2005CA2566184A1 Imidazopyridine compound
11/17/2005CA2566098A1 Therapeutic agent for keratoconjunctival disorder
11/16/2005EP1595871A2 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
11/16/2005EP1595867A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
11/16/2005EP1595543A2 Antineoplastic pharmaceutical compositions comprising taurolidine or taurultam and 5-fluorouracil
11/16/2005EP1594841A1 Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
11/16/2005EP1594498A2 Methods and compositions for the treatment of degenerative ocular pathologies
1 ... 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 ... 531